156 related articles for article (PubMed ID: 34747629)
21. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
22. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
Kim KA; Joo HJ; Park JY
Eur J Clin Pharmacol; 2011 Feb; 67(2):129-34. PubMed ID: 20972558
[TBL] [Abstract][Full Text] [Related]
23. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
24. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
26. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
[TBL] [Abstract][Full Text] [Related]
27. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
Zaidi F; Narang RK; Phipps-Green A; Gamble GG; Tausche AK; So A; Riches P; Andres M; Perez-Ruiz F; Doherty M; Janssen M; Joosten LAB; Jansen TL; Kurreeman F; Torres RJ; McCarthy GM; Miner JN; Stamp LK; Merriman TR; Dalbeth N
Rheumatology (Oxford); 2020 Sep; 59(9):2544-2549. PubMed ID: 31998961
[TBL] [Abstract][Full Text] [Related]
28. ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Liu J; Yang W; Li Y; Wei Z; Dan X
BMC Med Genet; 2020 Mar; 21(1):54. PubMed ID: 32183743
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive analysis of the association of common variants of ABCG2 with gout.
Yu KH; Chang PY; Chang SC; Wu-Chou YH; Wu LA; Chen DP; Lo FS; Lu JJ
Sci Rep; 2017 Aug; 7(1):9988. PubMed ID: 28855613
[TBL] [Abstract][Full Text] [Related]
30. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
[TBL] [Abstract][Full Text] [Related]
31. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
Łączna M; Malinowski D; Paradowska-Gorycka A; Safranow K; Dziedziejko V; Pawlik A
Eur J Clin Pharmacol; 2021 Nov; 77(11):1673-1678. PubMed ID: 34160668
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Carcieri C; Guido F; Avataneo V; Cariti G; Di Perri G; D'Avolio A
J Antimicrob Chemother; 2018 Jun; 73(6):1659-1664. PubMed ID: 29509884
[TBL] [Abstract][Full Text] [Related]
34. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
[TBL] [Abstract][Full Text] [Related]
35. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Wright DFB; Dalbeth N; Phipps-Green AJ; Merriman TR; Barclay ML; Drake J; Tan P; Horne A; Stamp LK
Br J Clin Pharmacol; 2018 May; 84(5):937-943. PubMed ID: 29341237
[TBL] [Abstract][Full Text] [Related]
36. No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat.
Stamp LK; Topless R; Miner JN; Dalbeth N; Merriman T
Rheumatology (Oxford); 2019 Mar; 58(3):547-548. PubMed ID: 30597115
[No Abstract] [Full Text] [Related]
37. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
Alivernini S; Mazzotta D; Zoli A; Ferraccioli G
Drugs Aging; 2009; 26(5):395-402. PubMed ID: 19552491
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
39. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
[TBL] [Abstract][Full Text] [Related]
40. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
